Introduction: Cancer immunotherapies were approved in recent years, including immune
checkpoint inhibitors. Experience with ipilimumab (CTLA-4 antagonist), nivolumab and …

In the past decade, the field of cancer immunotherapy has been revolutionized by immune
checkpoint blockade (ICB) technologies. Success across a broad spectrum of cancers has …

Immunotherapy has changed the treatment of patients with advanced cancer, with different
phase III trials showing durable responses across different histologies. This review focuses …

Immune cells play critical roles in tumor prevention as well as initiation and progression.
However, immune-resistant cancer cells can evade the immune system and proceed to form …

Background: Anaplastic thyroid carcinoma (ATC) is an aggressive thyroid malignancy that is
associated with poor prognosis. Current treatment options include surgery, radiation …

Background Immunotherapy is a firmly established pillar in the treatment of cancer,
alongside the traditional approaches of surgery, radiotherapy, and chemotherapy. Like …

Background The authors report results from the thyroid carcinoma cohort of the multicohort
phase 2 KEYNOTE‐158 study (NCT02628067), which evaluated pembrolizumab …

Chemotherapy with or without radiation is the standard therapy for anaplastic thyroid cancer
(ATC), although the response rate is not high and not durable. We describe a 62‐year‐old …

Immunotherapy has arisen in use in the field of oncology with seven immune checkpoint
inhibitors approved for the treatment of a variety of cancer histologies. Depending on the …

Background: Inhibitory antibodies against cytotoxic T lymphocyte antigen-4 (CTLA-4) and
programmed cell death-1 (PD-1) have antitumor efficacy and are now standard of care in the …